SFB TRR 102

Polymers under Multiple Constraints

Kolloquium

Thursday,

27th June 2013

at: **5.00 pm**

Hörsaal für
Theoretische Physik
Linnéstr 5
04103 Leipzig

Coffee will be served from 4.30 pm.

Prof. Dr. Roland Winter

Biophysical Chemistry, Faculty of Chemistry - Biophysical Chemistry,
TU Dortmund University,
Otto-Hahn-Strasse 6, D-44227 Dortmund,
Germany

Fibrillogenesis of Amyloidogenic Polypeptides – Effects of Membranes, Cosolvents, Crowding, and Search for Inhibitors

Using various physical-chemical tools and perturbation parameters, the effects of temperature, pressure, cosolvents as well as lipid interfaces and confining geometries on the various stages of the aggregation and fibrillation reaction of amyloidogenic peptides have been studied. First we show data on the experimentally derived static structure factor obtained for the protein insulin which has been analyzed with a statistical mechanical model based on the DLVO potential. The data reveal that the protein self-assembles into equilibrium clusters already at low concentrations in the pre-nucleation phase. Then, mechanistic details about the nucleation process and concurrent aggregation pathways of insulin and other disease related amyloidogenic peptides, such as IAPP and PrP, and the differential stability of the aggregate structures formed are discussed. Also solvational perturbations, accomplished by the addition of various salts and cosolvents have been explored. They exert pronounced and diversified effects on the unfolding, non-native assembly and fibril formation, which ultimately manifest in morphological variations of mature aggregates and fibrils. Finally, the presence of lipid interfaces and soft-matter confinement will be discussed, which drastically change the aggregation pathway as well as the kinetics of peptide aggregation. Using various model membrane systems, the influence of different membrane characteristics on the lipid-protein interaction has been revealed. Finally, we also discuss the cross-interaction of IAPP with other amyloidogenic peptides, such as insulin and Aβ, and present some data on small-molecule inhibitors of the fibrillation process of IAPP.